prikaz prve stranice dokumenta Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
  Download
PDF 1.61 MB
Scientific paper - Original scientific paper
Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
Biomedicines, 12 (2024), 2; 331. https://doi.org/10.3390/biomedicines12020331
Aurer, Igor; Jakšić, Ozren; Bašić-Kinda, Sandra; Mrđenović, Stefan; Ostojić-Kolonić, Slobodanka; Lozić, Dominik; Holik, Hrvoje; Novaković-Coha, Sabina; Berneš, Petra; Krečak, Ivan; Morić-Perić, Martina; Narančić, Marino; Mitrović, Zdravko; Valković, Toni

Cite this document

Aurer, I., Jakšić, O., Bašić Kinda, S., Mrđenović, S., Ostojić Kolonić, S., Lozić, D. ... Valković, T. (2024). Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases. Biomedicines, 12. (2). doi: 10.3390/biomedicines12020331

Aurer, Igor, et al. "Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases." Biomedicines, vol. 12, no. 2, 2024. https://doi.org/10.3390/biomedicines12020331

Aurer, Igor, Ozren Jakšić, Sandra Bašić Kinda, Stefan Mrđenović, Slobodanka Ostojić Kolonić, Dominik Lozić, Hrvoje Holik, et al. "Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases." Biomedicines 12, no. 2 (2024). https://doi.org/10.3390/biomedicines12020331

Aurer, I., et al. (2024) 'Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases', Biomedicines, 12(2). doi: 10.3390/biomedicines12020331

Aurer I, Jakšić O, Bašić Kinda S, Mrđenović S, Ostojić Kolonić S, Lozić D, and sur.. Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases. Biomedicines [Internet]. 2024 January 31 [cited 2024 December 06];12(2). doi: 10.3390/biomedicines12020331

I. Aurer, et al., "Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases", Biomedicines, vol. 12, no. 2, January 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:877674. [Accessed: 06 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
AuthorIgor Aurer
AuthorOzren Jakšić
AuthorSandra Bašić-Kinda
AuthorStefan Mrđenović
AuthorSlobodanka Ostojić-Kolonić
AuthorDominik Lozić
AuthorHrvoje Holik
AuthorSabina Novaković-Coha
AuthorPetra Berneš
AuthorIvan Krečak
AuthorMartina Morić-Perić
AuthorMarino Narančić
AuthorZdravko Mitrović
AuthorToni Valković
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Patients with lymphoid malignancies are at increased risk of death or prolonged infection due to COVID-19. Data on the influence of different antineoplastic treatment modalities on outcomes are conflicting. Anti-CD20 monoclonal antibodies increase the risk of prolonged infection. It is unclear whether this risk is affected by the choice of the antibody (rituximab vs. obinutuzumab). To elucidate the role of antineoplastic therapy on COVID-19 outcomes, KroHem collected data on patients with lymphoid malignancies diagnosed with COVID-19 between October 2020 and April 2021. A total of 314 patients were identified, 75 untreated, 61 off treatment and 178 on treatment. The mortality rate in untreated and off-treatment patients was 15% and 16%; 9% and 10% had prolonged infection. In the on-treatment group, 3% were still prolonged positive at time of data collection, 62% recovered and 35% died; 42% had prolonged infection. Disease type, use of anti-CD20 monoclonal antibodies, prior autologous stem-cell transplantation (ASCT) and line of treatment did not significantly affect mortality. Mortality was higher in older patients (p = 0.0078) and those treated with purine analogues (p = 0.012). Prolonged COVID-19 was significantly more frequent in patients treated with anti-CD20 monoclonal antibodies (p = 0.012), especially obinutuzumab, and purine analogues (p = 0.012). Age, prior ASCT and treatment line did not significantly affect risk of prolonged infection. These data suggest that increased age and use of purine analogues are main risk factors for increased mortality of COVID-19 in patients with lymphoid malignancies. Obinutuzumab further increases the risk of prolonged disease, but not of death, in comparison to rituximab. Epidemiological considerations should be taken into account when choosing the appropriate antineoplastic therapy for patients with lymphoid malignancies.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleBiomedicines
Numberingvol. 12, no. 2, 331
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines12020331
URN:NBNurn:nbn:hr:184:877674
Publication2024-01-31
Document URLhttps://www.mdpi.com/2227-9059/12/2/331
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-02-05 14:08:35